TG Therapeutics (TGTX) Reports Financial Results for Q4 and Full Year 2025

TG Therapeutics, Inc. (NASDAQ:TGTX) is one of the best cheap biotech stocks to buy now. TG Therapeutics, Inc. (NASDAQ:TGTX) released financial results for fiscal Q4 and full year 2025 on February 26. It reported fiscal Q4 and full year 2025 total revenue of $192.6 million and $616.3 million, respectively, including BRIUMVI U.S. net revenue of $182.7 million and $594.1 million, respectively. U.S. net product revenue for BRIUMVI reached $182.7 million for fiscal Q4 2025, reflecting around 20% quarterly growth over the prior year period, and $594.1 million for the full year of 2025, up approximately 92% year-over-year. Total global full-year 2025 revenue reached $616.3 million.

TG Therapeutics, Inc. (NASDAQ:TGTX) also reported the expansion of commercialization outside of the United States with its partner Neuraxpharm, with BRIUMVI now approved in several regions, including the European Union, United Kingdom, Switzerland, Australia, Kuwait, and the United Arab Emirates.

For the full-year 2026, the company’s target total global revenue is around $875-$900 million, including BRIUMVI U.S. net product revenue of approximately $825-$850 million.

TG Therapeutics, Inc. (NASDAQ:TGTX) is involved in the acquisition, development, and commercialization of novel treatments for B-cell malignancies and autoimmune diseases. The company’s product portfolio includes TG-1501, TG-1701, Ublituximab, and Umbralisib.

While we acknowledge the potential of TGTX as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.